Gilead Sciences (GILD) Has To Explore Ways to Grow Further
The healthcare firm Gilead Sciences Inc. (GILD) has lost nearly 5 percent of its stock over the past year. This arose even after the company’s drug was approved for COVID-19 therapy. Gilead Sciences specializes in the prevention of HIV as well as infectious diseases, including